WAVE Life Sciences Analyst Ratings and Price Targets: A Comprehensive Analysis

WAVE Life Sciences stock has seen varying analyst opinions, with 6 analysts evaluating the company over the last three months. The current average 12-month price target is $18.67, with a high estimate of $24.00 and a low estimate of $14.00. Analysts have made adjustments to their ratings and price targets, with Whitney Ijem of Canaccord Genuity maintaining a Buy rating and Tiago Fauth of Wells Fargo lowering their rating to Overweight.

Wave Life Sciences (NASDAQ:WVE) has been a subject of varying analyst opinions, with six analysts evaluating the company over the past three months. The current average 12-month price target is $18.67, ranging from a high estimate of $24.00 to a low estimate of $14.00. Analysts have made notable adjustments to their ratings and price targets, with Whitney Ijem of Canaccord Genuity maintaining a Buy rating and Tiago Fauth of Wells Fargo lowering their rating to Overweight.

Whitney Ijem of Canaccord Genuity initiated coverage on Wave Life Sciences with a Buy recommendation and a $19 per share target, citing multiple stock-moving catalysts in the near term. Ijem highlighted the company’s strong pipeline, including WVE-006, a GalNAc-RNA editing oligonucleotide targeted at alpha-1 antitrypsin deficiency, and WVE-007, an obesity candidate with an initial clinical data readout scheduled for Q4 2025. Additionally, the analyst pointed to an upcoming data readout for a 200mg version of WVE-006 from a Phase 1b/2a trial in Q3 2025, ahead of data for a higher 400mg single dose in the fall [1].

Tiago Fauth of Wells Fargo, on the other hand, lowered their rating to Overweight, indicating a more cautious outlook. Fauth’s analysis took into account the company’s recent setbacks and the challenging nature of its drug development pipeline. However, the analyst also noted the potential market potential for Wave Life Sciences’ experimental therapies, including WVE-N531 for Duchenne muscular dystrophy and WVE-003 for Huntington’s disease [2].

The company’s stock has seen a 90% loss from investing in the stock five years ago, and analysts have forecasted a decrease in earnings from ($0.84) to ($1.07) per share in the coming year. Despite this, the company has been active in its clinical development, submitting the first clinical trial application for WVE-006 and planning a virtual “R&D Day” to update investors on its progress [3].

Institutional ownership of Wave Life Sciences stands at 72.91%, indicating strong market trust in the company. However, insiders have sold more of their company’s stock than they have bought in the past three months, with a total of $176,044 sold compared to $0.00 bought. This could indicate a level of uncertainty among insiders about the company’s future prospects [4].

Wave Life Sciences continues to face challenges in its drug development efforts, but the recent adjustments in analyst ratings and price targets suggest a growing optimism about the company’s potential. As the company prepares for key data readouts and clinical trials, investors will be closely watching its progress and the impact of these catalysts on its stock price.

References:

[1] https://seekingalpha.com/news/4477809-wave-life-sciences-stock-new-buy-canaccord-genuity

[2] https://www.marketbeat.com/stocks/NASDAQ/WVE/

[3] https://www.marketbeat.com/stocks/NASDAQ/WVE/

[4] https://www.marketbeat.com/stocks/NASDAQ/WVE/